Chief Executive Officer
Vincent Milano joined Idera as Chief Executive Officer in December 2014. He most recently served as Chairman, President and Chief Executive Officer of ViroPharma, which was acquired by Shire Pharmaceuticals in January 2014. Under his stewardship, ViroPharma became a leading developer of innovative therapies for rare diseases, with the approval and commercialization of its lead product, Cinryze, for the treatment of hereditary angioedema in the United States and Europe. Mr. Milano currently serves on the Boards of Directors of Spark Therapeutics, Vanda Pharmaceuticals and VenatoRx. He received his Bachelor of Science degree in accounting from Rider College.